Viatris licenses Idorsia’s PhIII heart and lupus drugs with $350M upfront

Vi­a­tris has inked a deal with Idor­sia for a pair of late-stage drug can­di­dates in a move that may re­flect Vi­a­tris’ ef­forts to build its prod­uct de­vel­op­ment mus­cle.

The de­vel­op­ment and com­mer­cial­iza­tion part­ner­ship is based on two Phase III as­sets: P2Y12 in­hibitor se­latogrel for acute my­ocar­dial in­farc­tion and S1P1 re­cep­tor mod­u­la­tor cene­r­i­mod for sys­temic lu­pus ery­the­mato­sus (SLE). Vi­a­tris al­so has the right of first ne­go­ti­a­tion and first re­fusal for cer­tain oth­er Idor­sia as­sets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.